The commencement of the Phase IIa combination trial of RPL554 is encouraging and will add to the group’s Phase II data package. The dosing of the first patients in the Phase IIa trial follows the recent unequivocally positive results from the third and final part of the group’s Phase I/IIa trial of RPL554 in COPD. Verona Pharma now currently has two Phase IIa trials on-going with data from a Phase IIa clinical trial of RPL554 in asthma due in Q1 2016. We remain upbeat about Verona’s future prospects and look forward to headline data from the combination trial in Q2 2016.